Back to search
FDAFDA · Food and drugs·Recall number D-0523-2026

NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16

Published May 13, 2026 · Recall initiated: April 20, 2026

Summary

FDA records drug Class II recall D-0523-2026, published May 13, 2026 and initiated April 20, 2026. Recalling firm: Acella Pharmaceuticals, LLC; Status: Ongoing; Reported quantity: 6,336 bottles; Lot: Lot: 23F02, Expires: 05/2026; 25A37, Expires: 01/2028. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Chemical contamination; presence of lead and lithium above specification

What to do

Voluntary: Firm initiated · Letter

Get an email if NAPROXEN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NAPROXEN
Manufacturer
Acella Pharmaceuticals, LLC
Distributor
Nationwide
UPC
0342192619166
Lot
Lot: 23F02, Expires: 05/2026; 25A37, Expires: 01/2028.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16 recalled?

Yes. FDA published recall D-0523-2026 on May 13, 2026. Reported hazard: Chemical contamination; presence of lead and lithium above specification

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NAPROXEN. UPC: 0342192619166.